Michail_Petrov-96 Shares of Skye Bioscience ( NASDAQ: SKYE ) rallied 22% Monday after the biotech company highlighted the differences between its drug candidate nimacimab and Novo Nordisk’s ( NVO ) oral weight-loss drug candidate monlunabant. Skye said that no neuropsychiatric adverse events were observed in Phase.
Back to Health Page
